00:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
19:13 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Merrimack discontinues last clinical candidate

Merrimack discontinued development of MM-310 -- the company's last remaining product in clinical testing -- after a safety update showed that a Phase I trial in solid tumor patients "would not be able to reach...
18:58 , Apr 2, 2019 |  BC Extra  |  Financial News

Fusion raises $105M series B for radiopharmaceutical pipeline

Aiming to advance its pipeline of targeted α-particle radiopharmaceuticals for cancer, Fusion raised $105 million in an oversubscribed series B round led by Varian and new investor OrbiMed Advisors. Fusion Pharmaceuticals Inc. (Hamilton, Ontario) labels...
21:51 , Mar 7, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
01:35 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Horizon Phase III teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) said teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as thyroid eye disease. The company plans to submit...
19:46 , Feb 28, 2019 |  BC Extra  |  Clinical News

Horizon jumps after teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) added $7.16 (33%) $29.01 on Thursday after reporting that teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as...
21:40 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7 fusion-negative rhabdomyosarcoma. Screening of a panel of 1,912 approved or tool compound small molecule inhibitors in a...
21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
14:28 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Merrimack discontinues pancreatic cancer candidate after Phase II miss

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) reported that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic cancer. The company said it will discontinue the...
22:15 , Jun 27, 2018 |  BC Extra  |  Preclinical News

New small cell lung cancer subtype identified

In a Genes & Development paper , scientists at Cold Spring Harbor Laboratory identified a new subtype of small cell lung cancer defined by high levels of POU class 2 homeobox 3 (POU2F3; OCT11) and...